Related Experiment Video
Updated: Aug 6, 2026

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Published on: May 30, 2025
An integrated, iterative risk assessment framework for cannabis-containing products: Development and application
Marissa L Smith1, Jennifer R Cuzens-Guild2, Thomas J Martin2
1McKinney Regulatory Science Advisors, P.O. Box 9665, Henrico, VA, 23228, USA.
Abstract:
There is a growing market for cannabis-containing products in the US, many of which contain flavors, and a lack of consistent or aligned regulations. As such, the need for a product evaluation framework is critical. Building on decades of lessons in human health risk assessment in other industries, we developed a product evaluation framework for cannabis-containing products and implemented this with a representative cannabis product intended for inhalation with an electronic cannabis delivery system (ECDS). The framework is structured as an iterative, decision-based process that may be adaptable to evaluating products intended for different routes of exposure, in which each endpoint is integrated to guide additional testing and risk management decisions. Representative data on the formulation assessment and nonclinical product evaluation phases of the chemistry and toxicological testing are also provided for an inhalation product with discussion of limitations and insights of testing cannabis-containing samples with current standardized methods. Together, the framework and representative data exemplify use of an evidence-based risk assessment framework for cannabis products and offer practical guidance for manufactures seeking to responsibly develop products, as well as the development of regulatory guidance.
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinically Relevant Drug Product Specifications: Methods of Establishment
FDA Approved Drugs: Changes to Approved Drugs
